

The claims defining the invention are as follows:

1. A compound of Formula (I) or (Ia)



(I),



(Ia),


or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein:

each A is a bond, -O-, -S-, or $-NR^5-$;


each R is -X-Z;

X is $-(CR^7R^{7a})_m-$ or -C(=O)-;

Z has Formula (II) or (IIa):



(II),



(IIa);

wherein each B is a bond, $-(CR^7R^{7a})_m-$ or -C(=O)-;

each W is CR^7 or N;

each Y is $-(CR^7R^{7a})_m-$ or -O-;

each R^1 is aryl or heteroaryl;

each R^2 is H, alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl or alkoxycarbonyl;

each R^3 is aryl or heteroaryl;

each R^4 is H, or C_{1-4} alkyl;

R^5 is H, alkyl, $-(CR^7R^{7a})_m-C(=O)O-R^8$, alkenyl or alkynyl;

each R^{7a} and R^7 is independently H, F, Cl, Br, alkyl, haloalkyl, $-(CH_2)_m$-OH or $-(CH_2)_m$-C(=O)O-R^8;

each R^8 and R^{8a} is independently H, alkyl, haloalkyl, aminoalkyl, Boc-NH-alkyl, alkoxy, $-(CH_2)_m$-OH, $-(CH_2)_m$-C(=O)O-$(CH_2)_m$-H or $-(CH_2)_m$-OC(=O)-$(CH_2)_m$-H;

Boc is *tert*-butyloxycarbonyl;

each R^9 is independently $-(CR^7R^{7a})_t$-OH, $-(CR^7R^{7a})_m$-C(=O)O-R^8, $-(CR^7R^{7a})_m$-C(=O)O-$(CR^7R^{7a})_m$-OC(=O)O-R^8, $-(CR^7R^{7a})_m$-C(=O)O-$(CR^7R^{7a})_m$-OC(=O)-R^8, $-(CR^7R^{7a})_m$-C(=O)O-$(CR^7R^{7a})_m$-C(=O)O-R^8, $-(CR^7R^{7a})_t$-OC(=O)-R^8, or $-(CR^7R^{7a})_m$-C(=O)N$(R^8)_2$, with the proviso that when R^9 is $-(CR^7R^{7a})_t$-OH, R^3 is aryl, furyl, imidazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyrimidinyl, pyridazinyl, thiazolyl, diazolyl, triazolyl, tetrazolyl, thienyl, pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, pyranyl or triazinyl;



each n is independently 1, 2 or 3;

each t is independently 1, 2, 3 or 4;

each m is independently 0, 1, 2, 3 or 4; and

optionally each of aryl, heteroaryl, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, alkoxycarbonyl, aralkyl, heteroarylalkyl, aminoalkyl, alkoxy, furanyl, imidazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyrimidinyl, pyridazinyl, thiazolyl, diazolyl, triazolyl, tetrazolyl, thienyl, pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, pyranyl, triazinyl, heterocyclyl and heterocyclylalkyl described above, is independently substituted with one or more substituents which are the same or different, wherein the substituent is H, F, Cl, Br, I, alkyl, alkoxy, cyano, hydroxy, nitro, alkylamino, amino, trifluoromethyl, trifluoromethoxy, $-(CR^7R^{7a})_m$-C(=O)O-R^{8a}, haloalkyl-substituted aryl, halogen-substituted aryl, $-(CR^7R^{7a})_m$-C(=O)N$(R^{8a})_2$ or trifluoromethylsulfonyl.

2. The compound according to claim 1, wherein Z has Formula (III) or (IIIa):


(III),

(IIIa);

wherein each B is a bond or $-(CR^7R^{7a})_m$-;

each Y is $-(CR^7R^{7a})_m$- or -O-;

each R^{7a} and R^7 is independently H, F, Cl, Br, C_{1-4} alkyl, $-(CH_2)_m$-OH, C_{1-4} haloalkyl or $-(CH_2)_m$-C(=O)O-R^8;

each R^8 is independently H, C_{1-6} alkyl, C_{1-4} haloalkyl, amino-C_{1-4}-alkyl, Boc-NH-C_{1-4}-alkyl, C_{1-4} alkoxy, $-(CH_2)_m$-OH, $-(CH_2)_m$-C(=O)O-$(CH_2)_m$-H or $-(CH_2)_m$-OC(=O)-$(CH_2)_m$-H;









each R^9 is independently $-(CR^7R^{7a})_t$-OH, $-(CR^7R^{7a})_m$-C(=O)O-R^8, $-(CR^7R^{7a})_m$-C(=O)O-$(CR^7R^{7a})_m$-OC(=O)O-R^8, $-(CR^7R^{7a})_m$-C(=O)O-$(CR^7R^{7a})_m$-OC(=O)-R^8, $-(CR^7R^{7a})_m$-C(=O)O-$(CR^7R^{7a})_m$-C(=O)O-R^8, $-(CR^7R^{7a})_t$-OC(=O)-R^8or $-(CR^7R^{7a})_m$-C(=O)N$(R^8)_2$, with the proviso that when R^9 is $-(CR^7R^{7a})_t$-OH, R^3 is C_{6-10} aryl, furyl, imidazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyrimidinyl, pyridazinyl, thiazolyl, diazolyl, triazolyl, tetrazolyl, thienyl, pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, pyranyl or triazinyl;

each n is independently 1 or 2;

each t is independently 1, 2, 3 or 4; and

each m is independently 0, 1, 2, 3 or 4.

3. The compound according to claim 2, wherein Z is


,

,

,

,

,

,

,

or

;

wherein each R^7 and R^{7a} is independently H, methyl, ethyl, $-(CH_2)_m$-OH, $-(CH_2)_m$-C(=O)O-R^8 or propyl;

each R^8 is independently H, methyl, ethyl, propyl, isopropyl, butyl, 1-methylpropyl, 2-methylpropyl, aminomethyl, 1-amino-2-methylpropyl, 1-aminoethyl, 2-aminoethyl, 1-aminobutyl, 1-aminopropyl, 2-aminopropyl, Boc-NH-methyl, 1-Boc-NH-2-methylpropyl, 1-Boc-NH-ethyl, 2-Boc-NH-ethyl, 1-Boc-NH-butyl, 1-Boc-NH-propyl, 2-Boc-NH-propyl, methoxy, ethoxy, $-(CH_2)_m$-OH, $-(CH_2)_m$-C(=O)O-$(CH_2)_m$-H, $-(CH_2)_m$-OC(=O)-$(CH_2)_m$-H or *tert*-butyl; and

each R^9 is independently $-(CR^7R^{7a})_t$-OH, $-(CR^7R^{7a})_m$-C(=O)O-R^8, $-(CR^7R^{7a})_m$-C(=O)O-$(CR^7R^{7a})_m$-OC(=O)O-R^8, $-(CR^7R^{7a})_m$-C(=O)O-$(CR^7R^{7a})_m$-OC(=O)-R^8, $-(CR^7R^{7a})_t$-OC(=O)-R^8 or $-(CR^7R^{7a})_m$-C(=O)N$(R^8)_2$, with the proviso that when R^9 is


$-(CR^7R^{7a})_t-OH$, R^3 is phenyl, furyl, imidazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyrimidinyl, pyridazinyl, thiazolyl, diazolyl, triazolyl, tetrazolyl, thienyl, pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, pyranyl or triazinyl.

4. The compound according to claim 1, wherein R^3 is C_{6-10} aryl or 5-6 membered heteroaryl, and optionally each of the heteroaryl and aryl is independently substituted with one or more substituents which are the same or different, wherein the substituent is H, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, butyl, methoxy, ethoxy, methylamino, ethylamino, cyano, hydroxy, nitro, amino, trifluoromethyl, trifluoromethoxy, $-(CR^7R^{7a})_m-C(=O)O-R^{8a}$, $-(CR^7R^{7a})_m-C(=O)N(R^{8a})_2$ or trifluoromethylsulfonyl;

each R^{7a} and R^7 is independently H, F, Cl, Br, C_{1-4} alkyl, C_{1-4} haloalkyl, $-(CH_2)_m-OH$ or $-(CH_2)_m-C(=O)O-R^8$; and

each R^{8a} and R^8 is independently H, C_{1-4} alkyl, C_{1-4} haloalkyl, amino-C_{1-4}-alkyl, Boc-NH-C_{1-4}-alkyl, C_{1-4} alkoxy, $-(CH_2)_m-OH$, $-(CH_2)_m-C(=O)O-(CH_2)_m-H$ or $-(CH_2)_m-OC(=O)-(CH_2)_m-H$.

5. The compound according to claim 4, wherein R^3 has one of the following formulae:



wherein each X^1 is independently O, S, NR^{11} or $CR^{12}R^{12a}$;

each X^2, X^3, X^4, X^5 and X^6 is independently N or CR^{12}; wherein at most three or four of the X^2, X^3, X^4, X^5 and X^6 are N;

each R^{10} is independently H, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, butyl, methoxy, ethoxy, methylamino, ethylamino, cyano, hydroxy, nitro, amino, trifluoromethyl, trifluoromethoxy, $-(CR^7R^{7a})_m-C(=O)O-R^{8a}$, $-(CR^7R^{7a})_m-C(=O)N(R^{8a})_2$ or trifluoromethylsulfonyl;

each R^{11} is independently H, methyl, ethyl, propyl, isopropyl, butyl, trifluoromethyl, $-(CR^7R^{7a})_m-C(=O)N(R^{8a})_2$ or $-(CR^7R^{7a})_m-C(=O)O-R^{8a}$;

each R^{12} and R^{12a} is independently H, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, butyl, methoxy, ethoxy, methylamino, ethylamino, cyano, hydroxy, nitro, amino, trifluoromethyl, trifluoromethoxy, $-(CR^7R^{7a})_m-C(=O)O-R^{8a}$, $-(CR^7R^{7a})_m-C(=O)N(R^{8a})_2$ or trifluoromethylsulfonyl;


each R^{7a} and R^7 is independently H, F, Cl, Br, C_{1-4} alkyl, $-(CH_2)_m-OH$, C_{1-4} haloalkyl or $-(CH_2)_m-C(=O)O-R^8$;

each R^{8a} and R^8 is independently H, C_{1-4} alkyl, C_{1-4} haloalkyl, amino-C_{1-4}-alkyl, Boc-NH-C_{1-4}-alkyl, C_{1-4} alkoxy, $-(CH_2)_m$-OH, $-(CH_2)_m$-C(=O)O-$(CH_2)_m$-H or $-(CH_2)_m$-OC(=O)-$(CH_2)_m$-H;

each m is independently 0, 1, 2, 3 or 4; and

each p is independently 0, 1, 2 or 3.

6. The compound according to claim 5, wherein R^3 has one of the following formulae:



wherein each R^{10} is independently H, F, Cl, methyl, ethyl, cyano, hydroxy, nitro, amino, methoxy, ethoxy, trifluoromethyl, trifluoromethoxy, $-(CR^7R^{7a})_m$-C(=O)O-R^{8a}, $-(CR^7R^{7a})_m$-C(=O)N$(R^{8a})_2$ or trifluoromethylsulfonyl;

each R^{11} is independently H, methyl, ethyl, propyl, isopropyl, butyl, trifluoromethyl or $-(CR^7R^{7a})_m$-C(=O)O-R^{8a};

each R^{7a} and R^7 is independently H, methyl, ethyl, $-(CH_2)_m$-OH, $-(CH_2)_m$-C(=O)O-R^8 or propyl;

each R^8 and R^{8a} is independently H, methyl, ethyl, propyl, isopropyl, butyl, 2-methylpropyl, 1-methylpropyl, aminomethyl, 1-amino-2-methylpropyl, 1-aminoethyl, 2-aminoethyl, 1-aminobutyl, 1-aminopropyl, 2-aminopropyl, Boc-NH-methyl, 1-Boc-NH-2-methylpropyl, 1-Boc-NH-ethyl, 2-Boc-NH-ethyl, 1-Boc-NH-butyl, 1-Boc-NH-propyl, 2-Boc-NH-propyl, methoxy, ethoxy, $-(CH_2)_m$-OH, $-(CH_2)_m$-C(=O)O-$(CH_2)_m$-H, $-(CH_2)_m$-OC(=O)-$(CH_2)_m$-H or *tert*-butyl; and

each p is independently 0, 1, 2 or 3.


7. The compound according to claim 1, wherein R^1 is C_{6-10} aryl, and the aryl is independently substituted with one or more substituents which are the same or different, wherein the substituent is H, F, Cl, Br, cyano, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, nitro, 4-(trifluoromethyl)phenyl, 3,5-*bis*(trifluoromethyl)phenyl or trifluoromethyl;


R^2 is H, or C_{1-4} alkyl; and

R^5 is H, or C_{1-4} alkyl.


8. The compound according to claim 7, wherein R^1 is phenyl or a phenyl substituted with one or more substituents which are the same or different, wherein the substituent is H, F, Cl, Br, nitro, 4-(trifluoromethyl)phenyl, 3,5-*bis*(trifluoromethyl)phenyl or trifluoromethyl.


9. The compound according to claim 1 having Formula (IV) or (IVa),


(IV),


(IVa),

or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein Z has Formula (II) or (IIa):


(II),


(IIa);

wherein each B is a bond or $-(CR^7R^{7a})_m-$;

each W is CR^7 or N;

each Y is $-(CR^7R^{7a})_m-$ or -O-;

each R^2 is H, or C_{1-4} alkyl;

each R^3 is C_{6-10} aryl or 5-6 membered heteroaryl, and optionally each of the heteroaryl and aryl is independently substituted with one or more substituents which are the same or different, wherein the substituent is H, F, Cl, methyl, ethyl, propyl, cyano, trifluoromethyl, methoxy, $-(CR^7R^{7a})_m-C(=O)N(R^{8a})_2$ or $-(CR^7R^{7a})_m-C(=O)O-R^{8a}$;

each R^{7a} and R^7 is independently H, F, $-(CH_2)_m-OH$, $-(CH_2)_m-C(=O)O-R^8$ or C_{1-4} alkyl;

each R^8 and R^{8a} is independently H, amino-C_{1-4}-alkyl, Boc-NH-C_{1-4}-alkyl, C_{1-4} alkoxy, $-(CH_2)_m$-OH, $-(CH_2)_m$-C(=O)O-$(CH_2)_m$-H, $-(CH_2)_m$-OC(=O)-$(CH_2)_m$-H or C_{1-6} alkyl;

each R^9 is independently $-(CR^7R^{7a})_t$-OH, $-(CR^7R^{7a})_m$-C(=O)O-$(CR^7R^{7a})_m$-OC(=O)O-R^8, $-(CR^7R^{7a})_m$-C(=O)O-R^8, $-(CR^7R^{7a})_m$-C(=O)O-$(CR^7R^{7a})_m$-OC(=O)-R^8, $-(CR^7R^{7a})_t$-OC(=O)-R^8 or $-(CR^7R^{7a})_m$-C(=O)N$(R^8)_2$, with the proviso that when R^9 is $-(CR^7R^{7a})_t$-OH, R^3 is C_{6-10} aryl, furyl, imidazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyrimidinyl, pyridazinyl, thiazolyl, diazolyl, triazolyl, tetrazolyl, thienyl, pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, pyranyl or triazinyl;



each R^{13} is independently H, F, Cl, Br, cyano, nitro, 4-(trifluoromethyl)phenyl, 3,5-*bis*(trifluoromethyl)phenyl or trifluoromethyl;

each n is independently 1 or 2;

each t is independently 1, 2, 3 or 4; and

each m is independently 0, 1, 2, 3 or 4.

10. The compound according to claim 9, wherein Z has Formula (II) or (IIa):


(II),

(IIa);

wherein each B is a bond or $-(CR^7R^{7a})_m$-;

each W is CR^7 or N;

each Y is $-(CR^7R^{7a})_m$- or -O-;

each R^{7a} and R^7 is independently H, methyl, $-(CH_2)_m$-OH, $-(CH_2)_m$-C(=O)O-R^8, ethyl or propyl;

each R^8 is independently H, methyl, ethyl, propyl, isopropyl, butyl, 1-methylpropyl, 2-methylpropyl, *tert*-butyl, aminomethyl, 1-amino-2-methylpropyl, 1-aminoethyl, 2-aminoethyl, 1-aminobutyl, 1-aminopropyl, 2-aminopropyl, Boc-NH-methyl, 1-Boc-NH-2-methylpropyl, 1-Boc-NH-ethyl, 2-Boc-NH-ethyl, 1-Boc-NH-butyl, 1-Boc-NH-propyl, 2-Boc-NH-propyl, methoxy, ethoxy, $-(CH_2)_m$-OH, $-(CH_2)_m$-C(=O)O-$(CH_2)_m$-H or $-(CH_2)_m$-OC(=O)-$(CH_2)_m$-H;


each R^{8a} is independently H, methyl, ethyl, isopropyl or propyl;


each R^9 is independently $-(CR^7R^{7a})_t-OH$, $-(CR^7R^{7a})_m-C(=O)O-R^8$, $-(CR^7R^{7a})_m-C(=O)O-(CR^7R^{7a})_m-OC(=O)O-R^8$, $-(CR^7R^{7a})_m-C(=O)O-(CR^7R^{7a})_m-OC(=O)-R^8$, $-(CR^7R^{7a})_t-OC(=O)-R^8$, or $-(CR^7R^{7a})_m-C(=O)N(R^8)_2$, with the proviso that when R^9 is $-(CR^7R^{7a})_t-OH$, R^3 is phenyl, furyl, imidazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyrimidinyl, pyridazinyl, thiazolyl, diazolyl, triazolyl, tetrazolyl, thienyl, pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, pyranyl or triazinyl;

each m is independently 0, 1, 2, 3 or 4; and


each t is independently 1, 2, 3 or 4.

11. The compound according to claim 10, wherein Z is:







12. The compound according to claim 9, wherein each R^3 is independently:




13. The compound according to claim 1 having one of the following structures:




1 , 2 , 3 ,




4 ,




5 ,




6 ,




7 ,




8 ,




9 ,




10 ,




11 ,




12 ,




13




14




15




16




17




18




19




20




21




22




23




24




25




26




27




28




29




30




31




32




33




34




36




37




38




39




40




41




42




43




44




45




46




47




48




49




50




51




52




53




54




55




56




57




58




59




60




61




62




63




64




65




66




67




68




69




70




71




72




73




74




75




76




77




78




79




80




81




82




83




84




85




86




87




88




89




90




91




92




93




94




95




96




97




98




99




100




101




102




103




104




105




106




107




108




109




110




111




112




113




114




115




116




117




118




119 ,




120 ,




121 ,




122 ,




123 ,




124 ,




125 ,




126 ,




127 ,




128 ,




129 ,




130 ,




131 ,




132 ,




133 ,




134 ,




135 ,




136 ,




137 ,




138 ,




139 ,




140 ,




141 ,




142




143




144




145




146




147




148




149




150




151




152




153




154




156




157




158




159




160




161




162




163




164




165




166




167




168




169



170




171



172


and



173

or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof.

14. The compound according to claim 9 having Formula (IV):




(IV),


wherein n of formula (IV) is 2;

each R^{13} is independently F or Br;

R^2 is C_{1-4} alkyl; and

R^3 is  ; and

wherein Z has Formula (II):



(II),

n of formula (II) is 1;

R^9 is $-(CR^7R^{7a})_m-C(=O)O-R^8$, where m is 0 and R^8 is H;

B is a bond;

W is N; and

Y is $-(CR^7R^{7a})_m-$, where and each R^{7a} and R^7 is independently F.

15. A pharmaceutical composition comprising a compound according to any one of claims 1-14 and a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle or a combination thereof.

16. The pharmaceutical composition according to claim 15, further comprising an anti-HBV agent.

17. The pharmaceutical composition according to claim 16, wherein the anti-HBV agent is a HBV polymerase inhibitor, immunomodulator or interferon.

18. The pharmaceutical composition according to claim 16, wherein the anti-HBV agent is lamivudine, telbivudine, tenofovir, entecavir, adefovir dipivoxil, alfaferone, alloferon, celmoleukin, clevudine, emtricitabine, famciclovir, feron, hepatect CP, intefen, interferon α-1b, interferon α, interferon α-2a, interferon β-1a, interferon α-2, interleukin-2, mivotilate, nitazoxanide, peginterferon alfa-2a, ribavirin, roferon-A, sizofiran, euforavac, veldona, rintatolimod, phosphazid, heplisav, interferon α-2b, levamisole, or propagermanium.


19. Use of a compound according to any one of claims 1-14 in the manufacture of a medicament for preventing, managing, treating or lessening a viral disease or a HBV disease.


20. The use according to claim 19, wherein the viral disease or HBV disease is hepatitis B infection or a disease caused by hepatitis B infection.

21. The use according to claim 20, wherein the disease caused by hepatitis B infection is cirrhosis or hepatocellular carcinoma.

CLAIMS

1. A compound of Formula (I) or (Ia)


(I),


(Ia),


or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein:


each A is a bond, -O-, -S-, or -NR^5-;

each R is -X-Z;

X is -$(CR^7R^{7a})_m$- or -C(=O)-;

Z has Formula (II) or (IIa):


(II),


(IIa);

wherein each B is a bond, -$(CR^7R^{7a})_m$- or -C(=O)-;

each W is CR^7 or N;

each Y is -$(CR^7R^{7a})_m$-, -O-, -S-, -$S(=O)_q$- or -NR^6-;

each R^1 is aryl or heteroaryl;

each R^2 is H, alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl or alkoxycarbonyl;

each R^3 is aryl or heteroaryl;

each R^4 is H, or C_{1-4} alkyl;

R^5 is H, alkyl, -$(CR^7R^{7a})_m$-C(=O)O-R^8, alkenyl or alkynyl;

each R^6 is alkyl, $-(CR^7R^{7a})_m-C(=O)O-R^8$, alkenyl or alkynyl;

each R^{7a} and R^7 is independently H, F, Cl, Br, alkyl, haloalkyl, $-(CH_2)_m-OH$ or $-(CH_2)_m-C(=O)O-R^8$;

each R^8 and R^{8a} is independently H, alkyl, haloalkyl, aminoalkyl, Boc-NH-alkyl, alkoxy, $-(CH_2)_m-OH$, $-(CH_2)_m-C(=O)O-(CH_2)_m-H$ or $-(CH_2)_m-OC(=O)-(CH_2)_m-H$;

Boc is *tert*-butyloxycarbonyl;

each R^9 is independently $-(CR^7R^{7a})_t-OH$, $-(CR^7R^{7a})_m-S(=O)_q-R^8$, $-(CR^7R^{7a})_m-OS(=O)_q-R^8$, $-(CR^7R^{7a})_m-S(=O)_qO-R^8$, $-(CR^7R^{7a})_m-C(=O)-R^8$, $-(CR^7R^{7a})_m-C(=O)O-R^8$, $-(CR^7R^{7a})_m-C(=O)O-(CR^7R^{7a})_m-OC(=O)O-R^8$, $-(CR^7R^{7a})_m-C(=O)O-(CR^7R^{7a})_m-OC(=O)-R^8$, $-(CR^7R^{7a})_m-C(=O)O-(CR^7R^{7a})_m-C(=O)O-R^8$, $-(CR^7R^{7a})_t-OC(=O)-R^8$, triazolyl, tetrazolyl or $-(CR^7R^{7a})_m-C(=O)N(R^8)_2$, with the proviso that when R^9 is $-(CR^7R^{7a})_t-OH$, R^3 is aryl, furyl, imidazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyrimidinyl, pyridazinyl, thiazolyl, diazolyl, triazolyl, tetrazolyl, thienyl, pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, pyranyl or triazinyl;

each n is independently 1, 2 or 3;



each t is independently 1, 2, 3 or 4;

each m is independently 0, 1, 2, 3 or 4;

each q is independently 0, 1 or 2; and

optionally each of aryl, heteroaryl, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, alkoxycarbonyl, aralkyl, heteroarylalkyl, aminoalkyl, alkoxy, furanyl, imidazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyrimidinyl, pyridazinyl, thiazolyl, diazolyl, triazolyl, tetrazolyl, thienyl, pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, pyranyl, triazinyl, heterocyclyl and heterocyclylalkyl described above, is independently substituted with one or more substituents which are the same or different, wherein the substituent is H, F, Cl, Br, I, alkyl, alkoxy, cyano, hydroxy, nitro, alkylamino, amino, trifluoromethyl, trifluoromethoxy, $-(CR^7R^{7a})_m-C(=O)O-R^{8a}$, haloalkyl-substituted aryl, halogen-substituted aryl, $-(CR^7R^{7a})_m-C(=O)N(R^{8a})_2$ or trifluoromethylsulfonyl.

2. The compound according to claim 1, wherein Z has Formula (III) or (IIIa):


(III),

(IIIa);

wherein each B is a bond or $-(CR^7R^{7a})_m-$;

each Y is $-(CR^7R^{7a})_m-$, -O-, -S-, $-S(=O)_q-$ or $-NR^6-$;

each R^6 is C_{1-4} alkyl, $-(CR^7R^{7a})_m-C(=O)O-R^8$, C_{2-4} alkenyl or C_{2-4} alkynyl;

each R^{7a} and R^7 is independently H, F, Cl, Br, C_{1-4} alkyl, $-(CH_2)_m-OH$, C_{1-4} haloalkyl or $-(CH_2)_m-C(=O)O-R^8$;

each R^8 is independently H, C_{1-6} alkyl, C_{1-4} haloalkyl, amino-C_{1-4}-alkyl, Boc-NH-C_{1-4}-alkyl, C_{1-4} alkoxy, $-(CH_2)_m-OH$, $-(CH_2)_m-C(=O)O-(CH_2)_m-H$ or $-(CH_2)_m-OC(=O)-(CH_2)_m-H$;


each R^9 is independently $-(CR^7R^{7a})_t-OH$, $-(CR^7R^{7a})_m-C(=O)-R^8$, $-(CR^7R^{7a})_m-C(=O)O-R^8$, $-(CR^7R^{7a})_m-C(=O)O-(CR^7R^{7a})_m-OC(=O)O-R^8$, $-(CR^7R^{7a})_m-C(=O)O-(CR^7R^{7a})_m-OC(=O)-R^8$, $-(CR^7R^{7a})_m-C(=O)O-(CR^7R^{7a})_m-C(=O)O-R^8$, $-(CR^7R^{7a})_t-OC(=O)-R^8$, triazolyl, tetrazolyl or $-(CR^7R^{7a})_m-C(=O)N(R^8)_2$, with the proviso that when R^9 is $-(CR^7R^{7a})_t-OH$, R^3 is C_{6-10} aryl, furyl, imidazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyrimidinyl, pyridazinyl, thiazolyl, diazolyl, triazolyl, tetrazolyl, thienyl, pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, pyranyl or triazinyl;

each n is independently 1 or 2;

each t is independently 1, 2, 3 or 4; and

each m is independently 0, 1, 2, 3 or 4.

3. The compound according to claim 2, wherein Z is



wherein each R^6 is independently methyl, ethyl or propyl;

each R^7 and R^{7a} is independently H, methyl, ethyl, $-(CH_2)_m-OH$, $-(CH_2)_m-C(=O)O-R^8$ or propyl;

each R^8 is independently H, methyl, ethyl, propyl, isopropyl, butyl, 1-methylpropyl,

2-methylpropyl, aminomethyl, 1-amino-2-methylpropyl, 1-aminoethyl, 2-aminoethyl, 1-aminobutyl, 1-aminopropyl, 2-aminopropyl, Boc-NH-methyl, 1-Boc-NH-2-methylpropyl, 1-Boc-NH-ethyl, 2-Boc-NH-ethyl, 1-Boc-NH-butyl, 1-Boc-NH-propyl, 2-Boc-NH-propyl, methoxy, ethoxy, $-(CH_2)_m$-OH, $-(CH_2)_m$-C(=O)O-$(CH_2)_m$-H, $-(CH_2)_m$-OC(=O)-$(CH_2)_m$-H or *tert*-butyl; and


each R^9 is independently triazolyl, tetrazolyl, $-(CR^7R^{7a})_t$-OH, $-(CR^7R^{7a})_m$-C(=O)-R^8, $-(CR^7R^{7a})_m$-C(=O)O-R^8, $-(CR^7R^{7a})_m$-C(=O)O-$(CR^7R^{7a})_m$-OC(=O)O-R^8, $-(CR^7R^{7a})_m$-C(=O)O-$(CR^7R^{7a})_m$-OC(=O)-R^8, $-(CR^7R^{7a})_t$-OC(=O)-R^8 or $-(CR^7R^{7a})_m$-C(=O)$N(R^8)_2$, with the proviso that when R^9 is $-(CR^7R^{7a})_t$-OH, R^3 is phenyl, furyl, imidazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyrimidinyl, pyridazinyl, thiazolyl, diazolyl, triazolyl, tetrazolyl, thienyl, pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, pyranyl or triazinyl.

4. The compound according to claim 1, wherein R^3 is C_{6-10} aryl or 5-6 membered heteroaryl, and optionally each of the heteroaryl and aryl is independently substituted with one or more substituents which are the same or different, wherein the substituent is H, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, butyl, methoxy, ethoxy, methylamino, ethylamino, cyano, hydroxy, nitro, amino, trifluoromethyl, trifluoromethoxy, $-(CR^7R^{7a})_m$-C(=O)O-R^{8a}, $-(CR^7R^{7a})_m$-C(=O)$N(R^{8a})_2$ or trifluoromethylsulfonyl;

each R^{7a} and R^7 is independently H, F, Cl, Br, C_{1-4} alkyl, C_{1-4} haloalkyl, $-(CH_2)_m$-OH or $-(CH_2)_m$-C(=O)O-R^8; and

each R^{8a} and R^8 is independently H, C_{1-4} alkyl, C_{1-4} haloalkyl, amino-C_{1-4}-alkyl, Boc-NH-C_{1-4}-alkyl, C_{1-4} alkoxy, $-(CH_2)_m$-OH, $-(CH_2)_m$-C(=O)O-$(CH_2)_m$-H or $-(CH_2)_m$-OC(=O)-$(CH_2)_m$-H.

5. The compound according to claim 4, wherein R^3 has one of the following formulae:



wherein each X^1 is independently O, S, NR^{11} or $CR^{12}R^{12a}$;

each X^2, X^3, X^4, X^5 and X^6 is independently N or CR^{12}; wherein at most three or four of the X^2, X^3, X^4, X^5 and X^6 are N;

each R^{10} is independently H, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, butyl, methoxy, ethoxy, methylamino, ethylamino, cyano, hydroxy, nitro, amino, trifluoromethyl, trifluoromethoxy, $-(CR^7R^{7a})_m$-C(=O)O-R^{8a}, $-(CR^7R^{7a})_m$-C(=O)$N(R^{8a})_2$ or trifluoromethylsulfonyl;

each R^{11} is independently H, methyl, ethyl, propyl, isopropyl, butyl, trifluoromethyl, $-(CR^7R^{7a})_m-C(=O)N(R^{8a})_2$ or $-(CR^7R^{7a})_m-C(=O)O-R^{8a}$;

each R^{12} and R^{12a} is independently H, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, butyl, methoxy, ethoxy, methylamino, ethylamino, cyano, hydroxy, nitro, amino, trifluoromethyl, trifluoromethoxy, $-(CR^7R^{7a})_m-C(=O)O-R^{8a}$, $-(CR^7R^{7a})_m-C(=O)N(R^{8a})_2$ or trifluoromethylsulfonyl;


each R^{7a} and R^7 is independently H, F, Cl, Br, C_{1-4} alkyl, $-(CH_2)_m-OH$, C_{1-4} haloalkyl or $-(CH_2)_m-C(=O)O-R^8$;

each R^{8a} and R^8 is independently H, C_{1-4} alkyl, C_{1-4} haloalkyl, amino-C_{1-4}-alkyl, Boc-NH-C_{1-4}-alkyl, C_{1-4} alkoxy, $-(CH_2)_m-OH$, $-(CH_2)_m-C(=O)O-(CH_2)_m-H$ or $-(CH_2)_m-OC(=O)-(CH_2)_m-H$;

each m is independently 0, 1, 2, 3 or 4; and

each p is independently 0, 1, 2 or 3.

6. The compound according to claim 5, wherein R^3 has one of the following formulae:



wherein each R^{10} is independently H, F, Cl, methyl, ethyl, cyano, hydroxy, nitro, amino, methoxy, ethoxy, trifluoromethyl, trifluoromethoxy, $-(CR^7R^{7a})_m-C(=O)O-R^{8a}$, $-(CR^7R^{7a})_m-C(=O)N(R^{8a})_2$ or trifluoromethylsulfonyl;

each R^{11} is independently H, methyl, ethyl, propyl, isopropyl, butyl, trifluoromethyl or $-(CR^7R^{7a})_m-C(=O)O-R^{8a}$;

each R^{7a} and R^7 is independently H, methyl, ethyl, $-(CH_2)_m$-OH, $-(CH_2)_m$-C(=O)O-R^8 or propyl;

each R^8 and R^{8a} is independently H, methyl, ethyl, propyl, isopropyl, butyl, 2-methylpropyl, 1-methylpropyl, aminomethyl, 1-amino-2-methylpropyl, 1-aminoethyl, 2-aminoethyl, 1-aminobutyl, 1-aminopropyl, 2-aminopropyl, Boc-NH-methyl, 1-Boc-NH-2-methylpropyl, 1-Boc-NH-ethyl, 2-Boc-NH-ethyl, 1-Boc-NH-butyl, 1-Boc-NH-propyl, 2-Boc-NH-propyl, methoxy, ethoxy, $-(CH_2)_m$-OH, $-(CH_2)_m$-C(=O)O-$(CH_2)_m$-H, $-(CH_2)_m$-OC(=O)-$(CH_2)_m$-H or *tert*-butyl; and

each p is independently 0, 1, 2 or 3.


7. The compound according to claim 1, wherein R^1 is C_{6-10} aryl, and the aryl is independently substituted with one or more substituents which are the same or different, wherein the substituent is H, F, Cl, Br, cyano, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, nitro, 4-(trifluoromethyl)phenyl, 3,5-*bis*(trifluoromethyl)phenyl or trifluoromethyl;

R^2 is H, or C_{1-4} alkyl; and


R^5 is H, or C_{1-4} alkyl.

8. The compound according to claim 7, wherein R^1 is phenyl or a phenyl substituted with one or more substituents which are the same or different, wherein the substituent is H, F, Cl, Br, nitro, 4-(trifluoromethyl)phenyl, 3,5-*bis*(trifluoromethyl)phenyl or trifluoromethyl.

9. The compound according to claim 1 having Formula (IV) or (IVa),




(IV),




(IVa),

or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein Z has Formula (II) or (IIa):



(II),



(IIa);

wherein each B is a bond or $-(CR^7R^{7a})_m$-;

each W is CR^7 or N;

each Y is $-(CR^7R^{7a})_m-$, -O-, -S-, $-S(=O)_q-$ or $-NR^6-$;

each R^2 is H, or C_{1-4} alkyl;

each R^3 is C_{6-10} aryl or 5-6 membered heteroaryl, and optionally each of the heteroaryl and aryl is independently substituted with one or more substituents which are the same or different, wherein the substituent is H, F, Cl, methyl, ethyl, propyl, cyano, trifluoromethyl, methoxy, $-(CR^7R^{7a})_m-C(=O)N(R^{8a})_2$ or $-(CR^7R^{7a})_m-C(=O)O-R^{8a}$;

each R^6 is C_{1-4} alkyl;

each R^{7a} and R^7 is independently H, $-(CH_2)_m-OH$, $-(CH_2)_m-C(=O)O-R^8$ or C_{1-4} alkyl;

each R^8 and R^{8a} is independently H, amino-C_{1-4}-alkyl, Boc-NH-C_{1-4}-alkyl, C_{1-4} alkoxy, $-(CH_2)_m-OH$, $-(CH_2)_m-C(=O)O-(CH_2)_m-H$, $-(CH_2)_m-OC(=O)-(CH_2)_m-H$ or C_{1-6} alkyl;

each R^9 is independently triazolyl, tetrazolyl, $-(CR^7R^{7a})_t-OH$, $-(CR^7R^{7a})_m-C(=O)O-(CR^7R^{7a})_m-OC(=O)O-R^8$, $-(CR^7R^{7a})_m-C(=O)-R^8$, $-(CR^7R^{7a})_m-C(=O)O-R^8$, $-(CR^7R^{7a})_m-C(=O)O-(CR^7R^{7a})_m-OC(=O)-R^8$, $-(CR^7R^{7a})_t-OC(=O)-R^8$ or $-(CR^7R^{7a})_m-C(=O)N(R^8)_2$, with the proviso that when R^9 is $-(CR^7R^{7a})_t-OH$, R^3 is C_{6-10} aryl, furyl, imidazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyrimidinyl, pyridazinyl, thiazolyl, diazolyl, triazolyl, tetrazolyl, thienyl, pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, pyranyl or triazinyl;

each R^{13} is independently H, F, Cl, Br, cyano, nitro, 4-(trifluoromethyl)phenyl, 3,5-*bis*(trifluoromethyl)phenyl or trifluoromethyl;



each n is independently 1 or 2;

each t is independently 1, 2, 3 or 4;

each m is independently 0, 1, 2, 3 or 4; and

each q is independently 0, 1 or 2.

10. The compound according to claim 9, wherein Z has Formula (II) or (IIa):


(II),

(IIa);

wherein each B is a bond or $-(CR^7R^{7a})_m-$;

each W is CR^7 or N;

each Y is $-(CR^7R^{7a})_m-$, -O-, -S-, $-S(=O)_q-$ or $-NR^6-$;

each R^6 is methyl, ethyl or propyl;

each R^{7a} and R^7 is independently H, methyl, $-(CH_2)_m-OH$, $-(CH_2)_m-C(=O)O-R^8$, ethyl or propyl;

each R^8 is independently H, methyl, ethyl, propyl, isopropyl, butyl, 1-methylpropyl, 2-methylpropyl, *tert*-butyl, aminomethyl, 1-amino-2-methylpropyl, 1-aminoethyl, 2-aminoethyl, 1-aminobutyl, 1-aminopropyl, 2-aminopropyl, Boc-NH-methyl, 1-Boc-NH-2-methylpropyl, 1-Boc-NH-ethyl, 2-Boc-NH-ethyl, 1-Boc-NH-butyl, 1-Boc-NH-propyl, 2-Boc-NH-propyl, methoxy, ethoxy, $-(CH_2)_m-OH$, $-(CH_2)_m-C(=O)O-(CH_2)_m-H$ or $-(CH_2)_m-OC(=O)-(CH_2)_m-H$;


each R^{8a} is independently H, methyl, ethyl, isopropyl or propyl;


each R^9 is independently $-(CR^7R^{7a})_t-OH$, $-(CR^7R^{7a})_m-C(=O)O-R^8$, $-(CR^7R^{7a})_m-C(=O)O-(CR^7R^{7a})_m-OC(=O)O-R^8$, $-(CR^7R^{7a})_m-C(=O)O-(CR^7R^{7a})_m-OC(=O)-R^8$, $-(CR^7R^{7a})_t-OC(=O)-R^8$, triazolyl, tetrazolyl or $-(CR^7R^{7a})_m-C(=O)N(R^8)_2$, with the proviso that when R^9 is $-(CR^7R^{7a})_t-OH$, R^3 is phenyl, furyl, imidazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyrimidinyl, pyridazinyl, thiazolyl, diazolyl, triazolyl, tetrazolyl, thienyl, pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, pyranyl or triazinyl;


each m is independently 0, 1, 2, 3 or 4; and

each t is independently 1, 2, 3 or 4.


11. The compound according to claim 10, wherein Z is:














12. The compound according to claim 9, wherein each R^3 is independently:











,

,

,

,

,

,

,

or


.

13. The compound according to claim 1 having one of the following structures:



1
,

2
,

3
,

4
,

5
,

6
,




7 ,




8 ,




9 ,




10 ,




11 ,




12 ,




13 ,




14 ,




15 ,




16 ,




17 ,




18 ,




19 ,




20 ,




21 ,




22 ,




23 ,




24 ,




25 ,




26 ,




27 ,




28 ,




29 ,




30 ,




31 ,




32 ,




33 ,




34 ,




35 ,




36 ,




37 ,




38 ,




39 ,




40 ,




41 ,




42 ,




43 ,




44 ,




45 ,




46 ,




47 ,




48 ,




49 ,




50 ,




51 ,




52 ,




53 ,




54 ,




55 ,




56 ,




57 ,




58 ,




59 ,




60 ,




61 ,




62 ,




63 ,




64 ,




65 ,




66 ,




67 ,




68 ,




69 ,




70




71




72




73




74




75




76




77




78




79 ,




80 ,




81 ,




82 ,




83 ,




84 ,




85 ,




86 ,




87




88




89




90




91




92




93




94




95




96




97




98




99




100




101




102




103




104




105




106 ,




107 ,




108 ,




109 ,




110 ,




111 ,




112 ,




113 ,




114 ,




115 ,




116 ,




117 ,




118 ,




119 ,




120 ,




121 ,





122 ,





123 ,



124



125



126



127



128



129



130



131



132



133



134



135



136



137



138



139



140



141



142



143


144



145


146



147




148




149




150




151




152




153




154




155




156




157




158




159




160




161




162




163





164





165



166 ,



167 ,



168 ,


169 ,


170 ,


171 ,


172 and


173 ,

or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition comprising the compound according to any one of claims 1-13; and a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle or a combination thereof.

15. The pharmaceutical composition according to claim 14 further comprises an anti-HBV agent.

16. The pharmaceutical composition according to claim 15, wherein the anti-HBV agent is a HBV polymerase inhibitor, immunomodulator or interferon.

17. The pharmaceutical composition according to claim 15, wherein the anti-HBV agent is lamivudine, telbivudine, tenofovir, entecavir, adefovir dipivoxil, alfaferone, alloferon, celmoleukin, clevudine, emtricitabine, famciclovir, feron, hepatect CP, intefen, interferon α-1b, interferon α, interferon α-2a, interferon β-1a, interferon α-2, interleukin-2, mivotilate, nitazoxanide, peginterferon alfa-2a, ribavirin, roferon-A, sizofiran, euforavac, veldona, rintatolimod, phosphazid, heplisav, interferon α-2b, levamisole, or propagermanium.

18. Use of the compound according to any one of claims 1-13 or the pharmaceutical composition according to any one of claims 14-17 in the manufacture of a medicament for preventing, managing, treating or lessening a viral disease or a HBV disease in a patient.

19. The use according to claim 18, wherein the viral disease or HBV disease is hepatitis B infection or a disease caused by hepatitis B infection.

20. The use according to claim 19, wherein the disease caused by hepatitis B infection is cirrhosis or hepatocellular carcinoma.

21. A method for preventing, managing, treating or lessening a viral disease or a HBV disease in a patient, comprising administering to the patient with a therapeutically effective amount of the compound according to any one of claims 1-13 or the pharmaceutical composition according to any one of claims 14-17.

22. The method according to claim 21, wherein the viral disease or HBV disease is hepatitis B infection or a disease caused by hepatitis B infection.

23. The method according to claim 22, wherein the disease caused by hepatitis B infection is cirrhosis or hepatocellular carcinoma.

24. The compound according to any one of claims 1-13 or the pharmaceutical composition according to any one of claims 14-17 for use in preventing, managing, treating or lessening a viral disease or a HBV disease.

25. The compound or the pharmaceutical composition according to claim 24, wherein the viral disease or HBV disease is hepatitis B infection or a disease caused by hepatitis B infection.

26. The compound or the pharmaceutical composition according to claim 25, wherein the disease caused by hepatitis B infection is cirrhosis or hepatocellular carcinoma.